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ORIGINAL ARTICLE
Calcium electroporation for treatment of cutaneous metastases; a randomized
double-blinded phase II study, comparing the effect of calcium electroporation
with electrochemotherapy
H. Falka, L.W. Matthiessena, G. Woolerb and J. Gehla
aCenter for Experimental Drug and Gene Electrotransfer CEDGE, Department of Oncology, Herlev and Gentofte Hospital, University of
Copenhagen, Herlev, Denmark; bDepartment of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark
ABSTRACT
Background: Calcium electroporation is a novel anticancer treatment, which utilizes high voltage
pulses to permeabilize cell membranes and expose the cell to supraphysiological doses of calcium.
Preclinical studies on calcium electroporation have shown strikingly high tumor response with cell
necrosis. Calcium electroporation builds on the treatment electrochemotherapy, where chemotherapeu-
tic drugs, mostly bleomycin, are internalized by electroporation. This double-blinded randomized study
compared calcium electroporation to electrochemotherapy in terms of objective response measured
6 months after treatment.
Methods: Seven patients with a total of 47 cutaneous metastases from breast cancer and malignant
melanoma were included in the protocol. A total of 37 metastases were randomized and evaluated for
response, another 10 metastases were used for biopsy. This was a non-inferiority trial and metastases
were randomized individually in each patient to either intratumoral calcium or bleomycin followed by
application of electric pulses to tumor site. All metastases were treated once, and after 6-months of fol-
low-up, the randomization code was revealed.
Results: Objective response of calcium electroporation was 72% (13/18) with complete response in
66% (12/18). For electrochemotherapy, objective response was 84% (16/19) with complete response in
68% (13/19). There was no statistically significant difference between the two treatments (p¼ 0.5).
After 1 year, only three out of 25 metastases had relapsed. Ulceration, itching and exudation were
reported slightly more frequently in metastases treated with bleomycin, and hyperpigmentation was
only seen in metastases treated with bleomycin.
Conclusion: This study shows that calcium electroporation is feasible and effective in patients with
cutaneous metastases.
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Introduction
Up to 9% of all cancer patients develop cutaneous metasta-
ses [1] which can become exuding, bleeding and odorous,
why there is a need for good palliative treatment.
Electrochemotherapy describes the augmentation of cytotox-
icity of chemotherapeutic agents such as bleomycin by per-
meabilization of tumor cells using brief, high voltage electric
pulses (electroporation). Electrochemotherapy may be used
for cutaneous metastases from all tumor histologies [2–14].
It has consistently shown very high response rates after local
tumor treatment, and has quickly gained acceptance in many
European cancer centers.
Recently, introduction of supraphysiological doses of cal-
cium by electroporation was described, and it was shown that
this treatment modality led to a strikingly high tumor response
with cell necrosis associated with acute and severe ATP deple-
tion [15,16]. As calcium electroporation would have potential
as a local treatment of cutaneous metastases, we decided to
launch a double-blinded randomized controlled trial, to investi-
gate if calcium electroporation would be able to produce
responses similar to those observed for electrochemotherapy.
Patients and methods
Study design
This was a randomized double-blinded phase II study with a
primary endpoint to compare tumor response of calcium
electroporation with tumor response of electrochemotherapy
with intratumoral bleomycin in patients with cutaneous
metastases. The secondary endpoint was to evaluate toxicity
of calcium electroporation. A tertiary endpoint was set to cal-
culate whether the delivered current was affected in metasta-
ses treated with calcium chloride compared to metastases
treated with bleomycin.
The protocol was approved by the Danish Medicine
Agency, The Regional Ethics Committee and the Danish Data
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Protection Agency. The study was performed according
to Good Clinical Practice (GCP). Clinicaltrials.gov identifier:
NCT01941901.
Patients
Inclusion criteria were minimum of one histologically con-
firmed cutaneous metastasis of any histology and size from
0.5 to 3.0 cm. The patient should have been offered current
standard treatment. Patients who received endocrine or tar-
geted therapy, vinorelbine, capecitabine or weekly paclitaxel
could continue these treatments if there was no regression
of cutaneous metastases, otherwise at least 2 weeks since
previous treatment was required. Patients had to be at least
18 years old, ECOG performance status 2 [17] and have a
life expectancy of at least 3 months. Platelet count 50E9/l
and prothrombin time 40 s was required. Sexually active
men and women with childbearing potential had to use
adequate contraception during this trial. The patient had to
be able to understand the information and to sign informed
consent.
Exclusion criteria were previous bleomycin treatment with
more than 200,000 IU/m2, history of severe allergic reactions
associated with bleomycin, uncorrectable coagulation dis-
order, as well as pregnancy or lactation. Patients could not
be included if they participated in other clinical trials involv-
ing experimental drugs or if they had been involved in a trial
within 4 weeks prior to study drug administration.
Randomization
Randomization and evaluation was performed separately on
each metastasis, so that each patient would potentially have
both calcium electroporation and electrochemotherapy in dif-
ferent metastases. Block randomization was performed 1:1
separately into the two treatment arms.
A maximum of 10 metastases per patient were included. If
the patient had 1–6 metastases, all metastases were random-
ized and evaluated for response. Biopsies (before and/or after
treatment) were performed in patients with more than 6
metastases. If patients had more than 10 metastases, the
remaining were treated with standard intratumoral bleo-
mycin, but not included in the protocol.
The randomization lists were made by the Clinical
Research Unit and the pharmacy mixed calcium chloride and
bleomycin into syringes with appropriate dose for the calcu-
lated tumor volumes (Figure 1). The treating doctors had no
contact with the randomization or mixing of the drugs and
as calcium chloride and bleomycin are colorless and volumes
were identical, both doctors and patients were fully blinded
to content of the syringes. It was a once-only treatment and
after 6 months of follow-up, or when the patient was with-
drawn from the trial, the randomization code was revealed.
Previous treatments
For each metastasis, it was registered whether it was in a
previously irradiated area or in an area with lymphedema.
Concomitant treatments were recorded (Table 1).
Calcium and bleomycin doses
The dose of calcium chloride was estimated from preclinical
studies [15–18] and set to 9mg/ml (220mmol/l). The bleo-
mycin dose was set to 1000 IU/ml in accordance with
European Standard Operating Procedures for
Electrochemotherapy (ESOPE) [19]. Initially, the injected vol-
ume for both bleomycin and calcium chloride were 0.5ml/
cm3 tumor volume. After treatment of five patients, the
volume for the smaller tumors (0.5 cm3) was amended to
1ml/cm3. Tumor volume was calculated as ab2p/6, a¼ largest
diameter, b¼ largest diameter perpendicular to a.
A list of metastases with volumes was handed to the
pharmaceutical unit and syringes labeled with metastasis num-
ber were returned, containing either calcium or bleomycin.
Procedure
The treatment was performed in local anesthesia (lidocaine
with epinephrine) based on ESOPE [19]. The content of the
Figure 1. Illustration of study design At first visit, metastases were numbered and measured. Data were then brought to an external unit (the pharmacy) who
randomized and mixed calcium chloride and bleomycin into syringes labeled with numbers according to the metastases. At treatment, the blinded contents of the
syringes were injected intratumorally and followed by electroporation. It was a once-only treatment and the patients were followed for 6 months with regular
evaluation of tumor response and safety.
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numbered syringes was injected intratumorally and pulses
were delivered immediately after drug administration.
Electrodes with two parallel rows of needles (linear array)
were used, eight pulses of 0.1ms duration, and 400 V at a
frequency of 5 kHz were delivered using square wave pulse
generator (Cliniporator, IGEA, Italy for the first five patients
and Cliniporator Vitae IGEA, Italy for the last two patients).
Tumor response
Assessment of response was performed by clinical examin-
ation at day 15, 30, 60, 90, 180. Response was registered for
each target lesion and documented by digital photography
including a ruler. Response was evaluated similar to RECIST
v.1.1 [20] and defined as Complete Response (CR) –
disappearance of the lesion, Partial Response (PR) – at least
30% decrease in the largest diameter of the lesion,
Progressive Disease (PD) – at least 20% increase in the largest
diameter of the lesion and Stable Disease (SD) – neither 30%
decrease nor 20% increase of the largest diameter of the
lesion. To evaluate long lasting response, the patients were
examined again, if possible, 1 year after treatment.
Pathology
If the patients had more than 6 metastases, punch biopsies
were collected from additional metastases before and/or
after treatment (day 7). The biopsies were cut frozen and
H&E stained to determine the level of tumor cells, necrosis,
fibrosis and inflammation.
Safety assessment
Adverse events were recorded at the days of clinical examin-
ation using Common Toxicity Criteria for Adverse Events ver-
sion 4.0 [21], and pain was recorded using Numeric Rating
Scale for pain (NRS, 0 is no pain, 1–3 is mild pain, 4–6 is
moderate pain and 7–10 is severe pain) [22] before and after
treatment. As a measure of how patients felt about the pro-
cedure they were asked if they potentially would agree for
another session.
Statistical analysis
This study was set up as a non-inferiority study between cal-
cium electroporation and electrochemotherapy. Primary end-
point was to compare objective response (CR and PR) of the
two treatments. After reviewing existing data from electro-
chemotherapy with intratumoral bleomycin on small cutane-
ous metastases (3cm), we estimated the expected response
rate for electrochemotherapy to be 85% [2–12]. There were
no preexisting clinical data on calcium electroporation, but
we decided to accept a difference in response of 15%, thus
we estimated the expected objective response rate for cal-
cium electroporation to be 70%. To determine the required
number of metastases, we used a non-inferiority analysis and
Table 1. Patients demographics.
Patient Diagnosis Details Sex Age
Time since
diagnosis
(years)
Metastases
in other
organs Previous treatments
Concomitant
treatment
Metastases
included
1 Breast cancer þ ER
 HER2
Female 72 20 None Radiotherapy; tamoxifen;
letrozole; exemestane
Fulvestrant, 5
2 Breast cancer  ER
 HER2
Female 57 10 None Radiotherapy; taxotere;
anastrozole; exemestane;
tamoxifen; fulvestrant
None 7
3 Breast cancer þ ER
þ HER2
Female 58 19 Lung Letrozole; vinorelbineþ tras-
tuzumab;
tamoxifenþ trastuzumab
Exemestane
and tras-
tuzumab
9
4 Breast cancer þ ER
 HER2
Female 67 16 Bone Cyclophosphamideþmetho-
trexate þ5-FU; radiother-
apy; anastrozole;
exemestane; taxotere;
fulvestrant; capecitabine;
vinorelbine
Tamoxifen 8
5 Breast cancer þ ER
þ HER2
Female 70 7 None Taxotereþ trastuzumab;
tamoxifen; letrozole;
vinorelbineþ trastuzu-
mab; capecitabi-
neþ lapatinib; paclitax-
elþ trastuzumab;
radiotherapy
Trastuzumab 10
6 Malignant
melanoma
 BRAF Female 84 2 Lymph
nodes
Temozolomide (deemed
ineligible for Ipilimumab
due to age and PS)
None 2
7 Breast cancer þ ER
 HER2
Female 72 16 Bone Anastrozole; exemestane;
tamoxifen; capecitabine;
taxotere; fulvestrant; epi-
rubicin; vinorelbine; letro-
zole; radiotherapy
Megestrol
acetate
6
Time since primary cancer diagnose.At time of diagnosis the tumor cells were estrogen receptor positive, but relapse after 8 years showed estrogen receptor negative tumor cells.
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with a significance level of 0.05 and a power 80% the study
required 34 evaluable metastases.
All statistical analyses were done using SPSS v22. Tumor
response was analyzed using v2-test on objective responses
6 months after treatment. Difference in highest measured
current was analyzed using two tailed t-test with Bonferroni
correction and for adverse events only descriptive statistics,
as percentages, were used.
Results
Patients and metastases
Between October 2013 and February 2016, seven patients
with a total of 47 metastases were included in the protocol,
six patients had breast cancer and one patient had malignant
melanoma. Table 1 presents patient characteristics and previ-
ous and concomitant treatments at baseline.
Of the 47 included metastases, 37 metastases were
randomized and evaluated for response and 10 metastases
were used for biopsies. The median diameter of the 37
response evaluated metastases was 10mm (range: 5–25mm),
and the characteristics of the metastases were equally distrib-
uted between the two treatment arms (Table 2).
Tumor response
Response rate at 6 months of follow-up showed for calcium
electroporation an objective response of 72% (CR¼ 66%;
PR¼ 5%) and for electrochemotherapy an objective response
of 84% (CR¼ 68%; PR¼ 15%). There was no significant differ-
ence in objective response between calcium electroporation
and electrochemotherapy after 6 months (p¼ 0.5) (figure
2Aþ B). The 2-sided 95% CI for the outcome difference
between the 2 groups was 14.5%–38. 5% and did not cross
the 15% preselected non-inferiority margin why the study
proved non-inferiority for calcium electroporation.
A significantly different response was observed between
previous irradiated metastases and non-irradiated metastases
as a larger proportion of metastases in non-irradiated skin
showed complete response after 6 months (81% vs. 46%;
p¼ 0,036).
In one patient, three of the metastases progressed into
one coalescent, and verified malignant, tumor. The three
metastases, all in the bleomycin group, were included in the
response analysis as PD; however, measurement of the indi-
vidual metastases could not be performed.
Five patients had follow-up for 1 year after treatment, and
out of 25 metastases, three metastases had relapsed within a
year after treatment. All three metastases were treated with
calcium chloride.
Pathology
Punch biopsies from metastases were collected before treat-
ment and 7 days post-treatment from different metastases.
Pathology from both metastases treated with calcium electro-
poration and metastases treated with electrochemotherapy
showed less tumor infiltration and more necrosis compared
to untreated metastases (Figure 3).
Safety
No serious adverse events were observed. Brief contractions
of the underlying musculature were triggered by the electric
Table 2. Metastases used for response evaluation.
Calcium (n¼ 18) Bleomycin (n¼ 19)
Characteristics
Lesion size
Median diameter in mm (range) 9.5 (5–18) 11 (4–25)
Diagnosis
Malignant melanoma (n) 1 1
Breast cancer (n) 17 18
In previous irradiated area (n) 8 7
Concomitant treatment
Endocrine (n) 11 12
Trastuzumab (n) 3 3
Localization
Thorax (n) 10 15
Abdomen (n) 4 0
Other (n) 4 4
Treatment
Median doses in ml (range) 0.24 (0.03–1.21) 0.21 (0.03–0.55)
Median highest given current in A (range) 3.4 (0.9–8.2) 2.8 (1–9.6)
Median no. of pulses, n (range) 3 (1–7) 3 (1–7)
Response
Complete Response in % (n) 66% (12) 68% (13)
Partial Response in % (n) 5% (1) 15% (3)
Stable Disease in % (n) 16% (3) 0
Progressive Disease in % (n) 11% (2) 15% (3)
Adverse events
Ulceration in % (n) 38% (7) 68% (13)
Itch in % (n) 5% (1) 26% (5)
Exuding in % (n) 11% (2) 10% (2)
Hyperpigmentation in % (n) 0 26% (5)
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pulses, similar for both treatments, causing brief discomfort
in some patients. Otherwise, only CTC grade 1 was reported
after treatment (Table 2). Ulceration, itching and exudation
were reported slightly more frequently in metastases treated
with bleomycin compared to metastases treated with cal-
cium. A notable difference was seen in pigmentation, as only
metastases treated with bleomycin appeared hyperpig-
mented after treatment (26%) none of the metastases treated
with calcium had altered pigmentation (Figure 4).
Pain was not assessed in individual lesions, but as an over-
all experience. In the period after treatment, four of the
patients had no pain (NRS¼ 0), two patients reported mild
pain (NRS¼ 1–3) and one patient reported moderate pain
(NRS¼ 4–6). No patient wanted increase of pain medication.
Six out of seven patients expressed that they would agree
to undergo the treatment again if necessary.
Treatment and delivered current
A total of 18 metastases were treated with calcium chloride
and 19 metastases were treated with bleomycin. The median
injected volume and the number of applied electric pulses
were similar in the two treatment groups (Table 2). A ten-
dency of a higher delivered current was measured in meta-
stases treated with calcium chloride compared to metastases
treated with bleomycin, but the difference was not signifi-
cant. However, the measured delivered current was signifi-
cantly higher in metastases located in non-irradiated skin
compared to metastases located in previous irradiated skin
(p< 0.0001) (Figure 2D).
Follow-up
Follow-up for 6 months regarding response evaluation was
performed. One patient had progression of her cutaneous
metastases after 5 months and was withdrawn from the
protocol to start systemic chemotherapy (patient no. 5), her
metastases were measured the day of her exclusion and the
measurements were included in the final analysis. During the
6 months of response evaluation, the patients had either no
concurrent treatment or persistent treatment with endocrine
treatment or trastuzumab.
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Figure 2. Tumor response Metastases were treated at day ¼ 0 with either i.t. calcium or i.t. bleomycin in a randomized double-blinded study design. The metasta-
ses were treated once only and after 6 months of follow-up, the randomization code was revealed. A. Change in diameter over time: The graph illustrates change in
largest diameter over time for metastases treated with calcium chloride (red) and bleomycin (blue) (mean and standard deviation). The three non-measurable meta-
stases treated with bleomycin were not included. B. Percent change in tumor size 6 months after treatment: The graph illustrates a clear difference in tumor response
when subdivided into irradiated (CR¼ 46%) and non-irradiated (CR¼ 81%) metastases. The three non-measurable metastases treated with bleomycin were non-
irradiated, and are not illustrated in the graph, but included in the calculation. C. Percent metastases without progression: The graph illustrates progression in treated
metastases after treatment. After 6 months, 11% (2 out of 18) metastases treated with calcium had progressed, and 15% (3 out of 19) metastases treated with bleo-
mycin had progressed. D. Highest measured current: The graph illustrates that there is no significant difference in measured current between bleomycin and calcium
(p ¼ 0.5), but a significantly higher delivered current in non-irradiated metastases (light grey) compared to irradiated metastases (dark grey) (p< 0.0001).
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After the 6 months of response evaluation, additionally
five patients had progression with new cutaneous metastases
outside the treatment area. Two patients had a second ses-
sion of electrochemotherapy (patient no. 1 and 2), three
patients started systemic chemotherapy (patient no. 4, 5 and
7) and one patient had both a second session of electroche-
motherapy and started chemotherapy (patient no. 3). One
patient had complete regression and no further treatment,
until progression 18 months after treatment (patient no. 6)
[23]. Five out of the seven patients had a long-term follow-
up for 12 months after treatment, to monitor if there was
recurrence in the treated area.
Discussion
In this first clinical study with calcium electroporation, we
showed that calcium electroporation is safe and effective in
treatment of small cutaneous metastases equally with elec-
trochemotherapy in six patients with breast cancer and one
patient with malignant melanoma, a group of patients with
years of cancer history, and multiple treatments including
surgery, radiotherapy and several regimes of systemic
treatment.
Electrochemotherapy is an established treatment [19] and
has been used in treatment for cutaneous metastases for
years and been encompassed in guidance by the National
Institute for Health and Care Excellence (NICE) [24].
Electrochemotherapy can be performed locally with intratu-
moral injection of bleomycin, and with intravenous injection
of bleomycin. The latter is often preferred in larger treatment
areas.
In contrast, calcium electroporation is a novel treatment
where only a little experience is generated. However, preclin-
ical studies with calcium electroporation have shown impres-
sive results in cancer cell death and induction of tumor
regression [15]. Calcium is a vital intracellular signal molecule,
dependent on a low, tightly regulated intracellular calcium
concentration [25], which is overrun by calcium electropor-
ation. The more exact mechanism in how it leads to necrosis
in cancer cells is still not completely clear, but may be associ-
ated to their lack of tolerance towards the sudden and
severe ATP depletion [15,26,27].
As calcium chloride is an approved drug accessible in the
clinic, and the electroporation procedure well-integrated, it
was possible to integrate the treatment relatively fast in a
clinical protocol. Calcium electroporation may, in our opinion,
only be injected locally in order to avoid systemic effects of
the drug.
Response
In this study, we followed the guidelines from ESOPE [19]
according to applied voltage, pulses and drug injecting vol-
umes for treatment using intratumoral injection, but used
calcium chloride instead of bleomycin in half the number of
metastases. Here, we confirm an objective response of 84%,
similar to what previous clinical studies for electrochemother-
apy for small cutaneous metastases have shown (84%–100%)
Figure 3. Punch biopsies before and one week after treatment. A–C: Patient no. 3, with nine metastases from breast cancer on the right nates. A: Pre-treatment
biopsy: Skin biopsy with a moderate amount of tumor infiltration (black arrow) and fibrosis within the dermis. There is mild inflammation and no necrosis. B: Day 7.
Post-treatment with calcium electroporation: Ulcerated skin biopsy with the same amount of tumor infiltration as in the pretreatment biopsy and moderate fibrosis.
There is no inflammation or necrosis. C: Day 7. Post-treatment with electrochemotherapy: Ulcerated skin biopsy with no evidence of tumor but a large amount of
necrosis (grey arrow) and fibrosis and with mild inflammation. D–F: Patient no. 5 with ten metastases from breast cancer on her left breast and abdomen. D: Pre-
treatment biopsy: Skin biopsy with extensive tumor infiltration, moderate fibrosis and minimal inflammation. No evidence of necrosis. E: Day 7. Post-treatment with
calcium electroporation: Skin biopsy with less tumor infiltration than in the pretreatment biopsy and a moderate amount of necrosis and fibrosis. There is minimal
inflammation. F: Day 7. Post-treatment with electrochemotherapy: Skin biopsy with moderate tumor infiltration, necrosis and fibrosis. There is minimal
inflammation.
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[2–14] and we saw no significant difference in objective
response of calcium electroporation 6 months after treatment
(p¼ 0.5). Biopsies collected 7 days after treatment also
showed a markedly smaller number of cancer cells and
higher level of cell death in both metastases treated with cal-
cium electroporation and electrochemotherapy. Data were
evaluated 6 months after a once-only treatment, indicating
that this simple treatment may provide long-term responses
in cutaneous metastases, as only three out of 12 calcium
electroporated metastases recurred within a year.
During the 1 year of follow–up, six out of seven patients
(the six patients with breast cancer) had progression with
new cutaneous metastases outside the treatment area indi-
cating only a local treatment effect. The seventh patient,
with malignant melanoma, had complete remission in both
the treated metastases, but also in untreated metastases,
despite no further treatment, indicating a systemic immune
response [23]. Four months prior to inclusion the patient
had undergone standard electrochemotherapy on a large
area on her left limb including more than 100 metastases.
A systemic immune response after treatment with electro-
chemotherapy alone has not been described in patients
before.
Adverse events
Only local adverse events were reported and for both treat-
ments the adverse events were minimal. No grade 3 or 4 tox-
icities were reported, in fact only grade 1 local adverse
events were seen after both treatments.
Ulcers appeared in treatment areas after both calcium
electroporation and electrochemotherapy, but none of the
ulcers extended beyond the tumor margins, indicating that
normal skin was spared (Figure 4). The selectivity is already
known in electrochemotherapy, but for calcium electropor-
ation this finding supports data from preclinical in vitro stud-
ies [16,26,28].
There was a benefit in favor of calcium electroporation
with regards to cosmetic outcome as hyperpigmentation
appeared in 26% of the metastases treated with bleomycin
and no difference in pigmentation was seen in metastases
treated with calcium.
Response in previous irradiated metastases
The percentage of complete responses in metastases treated
with calcium electroporation and electrochemotherapy were
Figure 4. The top row show pictures from patient no. 2 with cutaneous metastases from breast cancer. Metastases 2 and 3 were treated with bleomycin and elec-
troporation, metastasis 4 were treated with calcium and electroporation. The two metastases labeled B were treated with bleomycin outside of protocol. A. before
treatment. B. Two weeks after treatment, shows crust on metastases no. 2, disappearing of metastases no. 3, and no visible chance in metastasis no. 4. C. Two
months after treatment, show clear hyperpigmentation equivalent to the area treated with bleomycin (metastases no. 2 and 3) and no change in pigmentation in
the area treated with calcium (metastases no. 4). Bottom row show pictures from patient no. 7 with cutaneous metastases from breast cancer. Metastases 1–3 were
treated with bleomycin and electroporation and metastases 4–6 were treated with calcium and electroporation. D. before treatment. E. Two weeks after treatment,
illustrates typical crust appearance, note the ulcer is not extending tumor margin. F. Six months after treatment, shows complete disappearance of metastases 1–5
and no change in metastasis no. 6.
ACTA ONCOLOGICA 317
almost alike (calcium, 66% vs. bleomycin, 68%). On the other
hand, irradiation seemed to strongly influence response as
81% of non-irradiated metastases had complete response
after 6-months of follow-up, in contrary to previously irradi-
ated metastases being only 46%. A contributing factor is
likely that in several of the cases the irradiated skin appeared
hard and fibrotic, making it difficult to insert the needles
from the electrode and reach the deeper tumor margin.
Furthermore, poor distribution of calcium or bleomycin in
the hard fibrotic skin is conceivable.
Measured delivered current was significantly lower in irra-
diated metastases compared to non-irradiated (Figure 2d),
which may be due to less conductivity in the fibrotic tissue
and challenges with insertion of the needle electrode.
Delivered current
There was no significant difference in measured delivered
current in the 2 treatment arms, which may be due to the
very small injection volumes relative to the tumor volume.
This difference in conductivity may be more relevant in treat-
ment of larger tumors with injection of larger volumes of
calcium.
Limitation
The study design required that the patients were followed
for 6 months without change of treatment regimen, which
made inclusion a challenge with mainly inclusion of breast
cancer patients. For these positive results to become firmly
established, confirmatory studies are needed for both meta-
stases from breast cancer but also from other histologies.
Perspectives
Calcium electroporation could be considered as a future
treatment for small cutaneous metastases, it is a simple treat-
ment and the better cosmetic outcome, compared to electro-
chemotherapy, is an advantage that not should be
underestimated for patients with visible cancer disease.
Though calcium cannot be administered intravenously as
bleomycin, it is easy to manage as it is not cytotoxic by itself.
The perspectives of calcium electroporation also include
treatment of larger tumors and internal tumors as new elec-
trodes for internal use are being developed. Finally, calcium
electroporation is cheap, compared to many anticancer treat-
ments, which also could be an advantage for low-income
countries.
Conclusion
This double-blinded randomized clinical study clearly indi-
cates that calcium electroporation is feasible in clinical set-
tings with minimal toxicity, and is effective in local tumor
reduction.
This study showed no significant difference in delivered
current in metastases treated with calcium compared to
metastases treated with bleomycin.
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